Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-P42
- Development stage
- Phase 3
- Lead developer
- Celltrion
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
CT-P42 is a biosimilar to aflibercept, developed by Celltrion, and marketed under the brand name Eydenzelt. It is a recombinant fusion protein that acts as a high-affinity inhibitor of vascular endothelial growth factor A (VEGF-A) and placenta growth factor (PlGF), thereby inhibiting angiogenesis. The drug is administered via intravitreal injection for the treatment of retinal diseases characterized by abnormal blood vessel growth and leakage, such as diabetic macular edema (DME). Phase III clinical trials have demonstrated therapeutic equivalence between CT-P42 and reference aflibercept in terms of efficacy, safety, pharmacokinetics, and immunogenicity in patients with DME. The product has been approved in South Korea and the European Union for ophthalmic indications including DME; regulatory review is ongoing in other regions[1][2][4][5][6][7][8].
- Brand names
- Eydenzelt
- Other names
- aflibercept biosimilar CT-P42biosimilar aflibercept (CT-P42)
02
Targets
VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on CT-P42.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-P42.